SecBot SecBot
424B5 ·Filed Apr 24, 2026

QTTB

Q32 Bio Inc.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago SEC0001193125-26-177170
Notable filing: 424B5
Actionable Insight ▼ Bearish

Monitor for actual sales volume and pricing under this ATM offering, as sustained dilution could pressure the stock price. The success of the bempikibart clinical program, particularly upcoming topline data in mid-2026, will be a key catalyst that could offset the negative sentiment from dilution.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$5.47
T+0 close · Apr 24, 2026 · via day close
Latest settled
+175.69%
T+60 · $15.08
Vs SPY
+170.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $5.47entry
  2. T+1 · 7mo ago +4.57%α +5.06% · $5.72
  3. T+5 · 7mo ago −7.86%α −8.26% · $5.04
  4. T+20 · 6mo ago +29.62%α +24.66% · $7.09
  5. T+60 · 4mo ago +175.69%α +170.91% · $15.08
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Q32 Bio Inc. is conducting an at-the-market (ATM) equity offering of up to $75 million in common stock through Cantor Fitzgerald. The company previously raised $14.2 million under a prior ATM agreement, which has now been terminated. The new offering allows for flexible, opportunistic capital raising based on market conditions, with proceeds intended for working capital and advancing its lead drug candidate, bempikibart, into future clinical trials for alopecia areata.

Key Facts

  • Q32 Bio is offering up to $75,000,000 in common stock through an at-the-market (ATM) offering with Cantor Fitzgerald.
  • The company has already raised $14,200,000 under a prior ATM agreement, which has been terminated.
  • The offering is subject to market conditions, with no minimum amount required, and shares will be sold at prevailing market prices.
  • Proceeds will be used for working capital, research, clinical development, and commercialization efforts, primarily for advancing bempikibart.
  • Investors purchasing shares will experience immediate dilution of $1.77 per share based on a $6.48 offering price.
  • The company is a smaller reporting company with a market cap of $95M and is focused on clinical-stage biologics for autoimmune diseases.

Financial Impact

Up to $75 million in gross proceeds, with net proceeds dependent on the number of shares sold and market prices. Investors will face $1.77 per share dilution based on a $6.48 price.

dilutioncashequity

Risk Factors

  • Significant shareholder dilution from the issuance of new shares.
  • The company has broad discretion over the use of proceeds, which may not lead to value-enhancing outcomes.
  • Future sales under the ATM program could depress the stock price if perceived as a sign of financial need.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-177170
Document: 0001193125-26-177170-index-headers.html0001193125-26-177170
Document: 0001193125-26-177170-index.html0001193125-26-177170
Document: 0001193125-26-177170.txt0001193125-26-177170

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026